Seattle Genetics, the dominant biotech firm in the region has its headquarters at Bothell’s Cascade Business Park. The facility has been studying human antibodies therapies practices since its existence in 1998. Its management on cancer is through the toxic payload delivered by the antibodies to destroy cancer.
Seattle Genetics market value is approximately $10 billion with a capacity of 900 staff. It is the leading biotech in Washington. The development plan for the firm is to invest more in research and business development as well as increasing the staff capacity to 1100 within the year.
Seattle Genetics leading drug Adcetris meant for Hodgkin lymphoma is currently under extensive tests before its launched in the market. The lymph system cancer is feared to spread to other body organs.
The international, oncology and a multi-product evolving company has various drugs in the pipeline. The co-founder and CEO, Clay Siegall plans to set the firm apart from several other biotech companies. He strategizes to building Seattle Genetics into a great business. Besides the typical drug development, the CEO plans for the company to focus on all difficulties in the international marketing of its new-fangled drugs. The strategy is a solution developed from previous challenges faced during the global launch of Takeda oncology that raised funds to enable the Adcetris research. However, the Takeda collaborations contributed to the steady expansion of Seattle Genetics to Switzerland.
Seattle Genetics revenue for the year 2016 was approximately $418 million, 46% increase from 2014. Within the past year, the company valuation was noted to have increased by over 50% in addition to the tripled stock value to $66 from $20. Due to its commitment to research, Seattle Genetics has invested $376 million, an increase of 64% investment from the year 2014.
Seattle genetics focus on drugs that aim at killing antigens, protein molecules which trigger production of antibodies by the immune system. The ADC drugs attach to the tumor cells in Hodgkin lymphoma or other diseases. It kills them by delivering a venom that is harmless to other cells. The approach minimizes health cell damage that can happen during chemotherapy radiation.
About Clay Siegall
Clay Siegall, the co-founder, and president of Seattle Genetics serves as the chair of the board of directors. Through the efforts of its founder, the company has built different channels of cancer, antibody-based therapies. Clay has assisted in the firm capital-raising events that earned over $1.2 billion. He worked as the director of Ultragenyx Pharmaceutical, Washington Roundtable, and Alder BioPharmaceuticals.
Mr. Siegall holds a degree in zoology and Ph.D. in Genetics from the University of Maryland and Washington University respectively. His vision to life improvement through cancer treatment therapies on the unmet needs triggered the establishment of the Seattle Genetics. The firm focuses on cancer scientific inventions, drug expansion, and investigation practices. Clay has led the company to acquire numerous strategic licenses for the ADC technology generating over $350 million.